ECM-based bioactive microencapsulation significantly improves islet function and graft performance

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Endocrinology

Background:

• Microencapsulation is crucial for islet transplantation in diabetes therapy but faces challenges with graft performance.
• Decellularized extracellular matrix (ECM) shows potential in enhancing cell function, particularly for tissue-specific applications.

Purpose of the Study:

• To develop and evaluate a porcine pancreatic ECM (pECM)-based microencapsulation platform for pancreatic islet transplantation.
• To assess the efficacy of pECM microencapsulation in improving islet viability, function, and therapeutic outcomes in a diabetic mouse model.

Main Methods:

• Development of microcapsules using decellularized porcine pancreatic ECM (pECM) to encapsulate murine pancreatic islets.
• In vitro assessment of insulin secretion, cell proliferation, and cytokine-induced cytotoxicity.
• In vivo evaluation of glucose tolerance and glycemic correction in immunocompetent diabetic mice.

Main Results:

• pECM-encapsulated islets exhibited superior insulin secretion and enhanced intra-islet ECM formation compared to alginate-encapsulated islets.
• pECM encapsulation provided temporary protection against cytokine-induced cytotoxicity in vitro.
• In vivo, pECM encapsulation led to significant glucose tolerance improvement and 100% glycemic correction in diabetic mice without immunosuppression.

Conclusions:

• pECM-based microencapsulation creates a natural pancreatic niche that restores isolated islet function and viability.
• This platform offers a safe and effective strategy for islet transplantation, obviating the need for immunosuppression.
• pECM microencapsulation presents a viable therapeutic approach for diabetes, warranting further preclinical investigation.